In the setting of EGFR-mutated NSCLC, the third-generation EGFR TKI osimertinib is the current first-line standard of care, although eventual progression is virtually inevitable. Secondary EGFR and MET alterations have been found to account for 25 % to 50 % of cases of resistance.
The highly selective and potent RET kinase inhibitor selpercatinib has been implemented in the treatment of lung cancer harboring RET gene fusions. At the same time, the combination of platinum, pemetrexed and pembrolizumab is an established first-line standard of care for patients without EGFR or ALK alterations. The aim of the randomized, open-label, phase III LIBRETTO-431 study was to define the optimal first-line regimen for patients with RET-fusion–positive NSCLC.
Approximately 30 % to 40 % of patients with non–small-cell lung cancer (NSCLC) are diagnosed with resectable disease. Depending on the stage, the risk of disease recurrence remains high in spite of treatment, which calls for more effective strategies. For patients with resectable ALK-positive NSCLC, the guidelines recommend adjuvant platinum-based chemotherapy, while immunotherapy is not recommended.
It is a pleasure to present you the memo inOncology 2023. This time we report on the ESMO Congress held in Madrid, Spain, from 20th to 24th October 2023. It was an outstanding scientific and educational event with more than 33,000 participants from 155 countries.
Capecitabine plus temozolomide (CAPTEM) is widely used for the treatment of advanced, unresectable, and progressive neuroendocrine tumors (NETs). However, data are limited regarding its association with radioligand therapy (RLT)/peptide receptor radionuclide therapy (PRRT).
Neuroendocrine neoplasms (NENs) comprise a rare group of heterogenous neoplasms that originate from cells with a neuroendocrine phenotype and can arise in almost every organ or region of the body [1]. They display a variable biological behavior; in fact, in some patients the disease may be stable for years, whereas in others, it might be very aggressive [2].
WCLC 2023 - Paul Van Schil In this exclusive video int ...
WCLC 2023 - Yasushi Goto Yasushi Goto discusses the ef ...
The 8th edition of the TNM classification of lung cancers has been in effect since 2017. These recommendations have been summarized in publications issued by the Union for International Cancer Control (UICC), the American Joint Committee on Cancer (AJCC), and the International Association for the Study of Lung Cancer (IASLC).
Surgery in the form of maximum cytoreduction is recommended to reduce all visible disease in the setting of resectable malignant pleural mesothelioma. Extra-pleural pleurectomy/decortication has been established as the predominant approach offered worldwide.
